Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. presents new somatostatin receptor sst3 antagonists

May 28, 2010

FDA approves Lumizyme for late-onset Pompe's disease

May 27, 2010

Cytochroma reports phase I/II data on CTAP-101 in CKD-associated hyperparathyroidism

May 27, 2010

ONO-5334 shows promise in postmenopausal osteoporosis

May 26, 2010

Elagolix meets all efficacy endpoints in phase II trial in endometriosis

May 25, 2010

NORD awards Shire for developing VPRIV in Gaucher's disease

May 25, 2010

Vagifem 10-mcg tablets replace 25-mcg formulation for atrophic vaginitis

May 25, 2010

Galapagos initiates clinical studies of GLPG-0492 for cachexia

May 21, 2010

Metabolex describes new GPR120 agonists for type 2 diabetes

May 21, 2010

Zydus-Cadila claims new thyroid hormone receptor beta ligands

May 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...